Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Cited In for PubMed (Select 19118696)

1.

Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.

Agarwal A, Rhoades WR, Hanout M, Soliman MK, Sarwar S, Sadiq MA, Sepah YJ, Do DV, Nguyen QD.

Clin Ophthalmol. 2015 Jun 5;9:1001-15. doi: 10.2147/OPTH.S74959. eCollection 2015. Review.

2.

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population.

Basheer K, Mensah E, Khanam T, Minakaran N.

Clin Ophthalmol. 2015 May 28;9:959-65. doi: 10.2147/OPTH.S76754. eCollection 2015.

3.

Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.

Batioglu F, Demirel S, Özmert E, Abdullayev A, Bilici S.

BMC Ophthalmol. 2015 Apr 11;15:40. doi: 10.1186/s12886-015-0025-z.

4.

Defining response to anti-VEGF therapies in neovascular AMD.

Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly S, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y.

Eye (Lond). 2015 Jun;29(6):721-731. doi: 10.1038/eye.2015.48. Epub 2015 Apr 17. Review.

PMID:
25882328
5.

Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome.

Beykin G, Grunin M, Averbukh E, Banin E, Hemo Y, Chowers I.

BMC Ophthalmol. 2015 Apr 11;15:39. doi: 10.1186/s12886-015-0019-x.

6.

Current perspectives on ranibizumab.

Dedania VS, Bakri SJ.

Clin Ophthalmol. 2015 Mar 20;9:533-42. doi: 10.2147/OPTH.S80049. eCollection 2015. Review.

7.

Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy.

Prea SM, Chan EC, Dusting GJ, Vingrys AJ, Bui BV, Liu GS.

J Ophthalmol. 2015;2015:201726. doi: 10.1155/2015/201726. Epub 2015 Mar 3. Review.

8.

Missed Hospital Appointments of Patients Receiving Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration.

Karampelas M, Pefkianaki M, Rees A, Gill N, Kotecha A, Hamilton R, Nikita E, Patel PJ.

Ophthalmol Ther. 2015 Jun;4(1):43-9. doi: 10.1007/s40123-015-0031-5. Epub 2015 Mar 14.

9.

Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration.

Schütze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U.

Am J Ophthalmol. 2015 Jun;159(6):1100-1114.e1. doi: 10.1016/j.ajo.2015.02.020. Epub 2015 Mar 10.

10.

YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self-Renewal and Vascular Mimicry of Stem-Like Cells.

Bora-Singhal N, Nguyen J, Schaal C, Perumal D, Singh S, Coppola D, Chellappan S.

Stem Cells. 2015 Jun;33(6):1705-18. doi: 10.1002/stem.1993.

PMID:
25754111
11.

Intravitreal ranibizumab for subfoveal choroidal neovascularization from age-related macular degeneration with combined severe diabetic retinopathy.

Han SY, Bae JH, Oh J, Yu HG, Song SJ.

Diabetes Metab J. 2015 Feb;39(1):46-50. doi: 10.4093/dmj.2015.39.1.46. Epub 2015 Feb 16.

12.

Blood flow velocity measured using the Retinal Function Imager predicts successful ranibizumab treatment in neovascular age-related macular degeneration: early prospective cohort study.

Böhni SC, Howell JP, Bittner M, Faes L, Bachmann LM, Thiel MA, Schmid MK.

Eye (Lond). 2015 May;29(5):630-6. doi: 10.1038/eye.2015.10. Epub 2015 Feb 27.

PMID:
25721520
15.

Therapeutic Modalities of Exudative Age-related Macular Degeneration.

Mavija M, Alimanovic E, Jaksic V, Kasumovic SS, Cekic S, Stamenkovic M.

Med Arch. 2014 Jun;68(3):204-208. Epub 2014 May 31. Review.

16.

Stem cell-based therapies for age-related macular degeneration: current status and prospects.

Mu Y, Zhao M, Su G.

Int J Clin Exp Med. 2014 Nov 15;7(11):3843-52. eCollection 2014. Review.

17.

The sustained delivery of resveratrol or a defined grape powder inhibits new blood vessel formation in a mouse model of choroidal neovascularization.

Kanavi MR, Darjatmoko S, Wang S, Azari AA, Farnoodian M, Kenealey JD, van Ginkel PR, Albert DM, Sheibani N, Polans AS.

Molecules. 2014 Oct 30;19(11):17578-603. doi: 10.3390/molecules191117578.

18.

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results.

Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, Ambresin A, Mantel I.

Eye (Lond). 2015 Mar;29(3):342-9. doi: 10.1038/eye.2014.258. Epub 2014 Nov 7. Erratum in: Eye (Lond). 2015 Mar;29(3):450-1.

PMID:
25359289
19.

Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review.

Castillo MM, Mowatt G, Lois N, Elders A, Fraser C, Amoaku W, Burr JM, Lotery AJ, Ramsay CR, Azuara-Blanco A.

Eye (Lond). 2014 Dec;28(12):1399-406. doi: 10.1038/eye.2014.214. Epub 2014 Sep 19. Review.

PMID:
25233820
20.

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS.

Cochrane Database Syst Rev. 2014 Aug 29;8:CD005139. doi: 10.1002/14651858.CD005139.pub3. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk